SPARC Share Price Performance
₹145.73
-71.29 (-32.85%)
Price ₹145.73
Share Price₹145.73
SPARC Community Narratives
There are no narratives available yet.
Recent SPARC News & Updates
No updates
Sun Pharma Advanced Research Company Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -9.20
- Gross Margin
- 57.33%
- Net Profit Margin
- -413.54%
- Debt/Equity Ratio
- -119.0%
Sun Pharma Advanced Research Company Limited Competitors
About SPARC
- Founded
- 2006
- Employees
- 316
- CEO
- WebsiteView website
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
Indian Market Performance
- 7 Days: 0.2%
- 3 Months: 5.2%
- 1 Year: -2.4%
- Year to Date: -1.1%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. Similarly, the market is flat for the past 12 months. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading